PEG-Intron [peginterferon alfa-2b]/REBETOL [ribavirin] vs PEGIntron/SCH 503034 [boceprevir] with and without ribavirin in chronic hepatitis C HCV [hepatitis C virus]-1 peginterferon alfa/ribavirin null responders: a SCH 503034 dose-finding phase 2 study.

Trial Profile

PEG-Intron [peginterferon alfa-2b]/REBETOL [ribavirin] vs PEGIntron/SCH 503034 [boceprevir] with and without ribavirin in chronic hepatitis C HCV [hepatitis C virus]-1 peginterferon alfa/ribavirin null responders: a SCH 503034 dose-finding phase 2 study.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2013

At a glance

  • Drugs Boceprevir; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms RESPOND 1
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 May 2008 Results were reported at the Digestive Disease Week 2008.
    • 15 May 2008 Results reported at DDW 2008, according to a Schering-Plough media release (oral presentation 162; abstract 442360).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top